INTERCEPT Platelets: Journal Articles

1. Osselaer JC, Messe N, Hervig T, et al. A prospective observational cohort safety study of 5106 platelet transfusions with components prepared with photochemical pathogen inactivation treatment. Transfusion 2008 Mar 13 (Epub ahead of print).
   View abstract >
2. Osselaer JC, Cazenave JP, Lambermont M, et al. An active haemovigilance programme characterizing the safety profile of 7437 platelet transfusions prepared with amotosalen photochemical treatment. Vox Sang. 2008 May;94(4):315-23.
   View abstract >
3. Tynngård N, Johansson BM, Lindahl TL, et al. Effects of INTERCEPT pathogen inactivation on platelet function as analysed by free oscillation rheometry. Transfus Apher Sci. 2008 Feb;38(1):85-8.
   View abstract >
4. Cognasse F, Osselaer JC, Payrat JM, et al. Release of immune modulation factors from platelet concentrates during storage after photochemical pathogen inactivation treatment. Transfusion 2008 Feb 21 (Epub ahead of print)
   View abstract >
5. Tice RR, Gatehouse D, Kirkland D, Speit G. The pathogen reduction treatment of platelets with S-59 HCI (Amotosalen) plus ultraviolet A light: Genotoxicity profile and hazard assessment. Mutation Research 2007; 630:50-68.
   View abstract >
6. Brecher ME, Hay S, Corash L, et al. Evaluation of bacterial inactivation in prestorage pooled, leukoreduced, whole blood-derived platelet concentrates suspended in plasma prepared with photochemical treatment. Transfusion 2007;47(10):1896-1901.
   View abstract >
7. Nussbaumer W, Allersdorfer D, Grabmer C, et al. Prevention of transfusion of platelet components contaminated with low levels of bacteria: a comparison of bacterial culture and pathogen inactivation methods. Transfusion 2007, 47(7):1125-1133.
   View abstract >
8. Sawyer L, Hanson C, Castro G, e al. Inactivation of parvovirus B19 in human platelet concentrates by treatment with amotosalen and ultraviolet A illumination. Transfusion 2007; 47(6):1062-1070.
   View abstract >
9. Lozano M, Galan A, Mazzara R, et al. Leukoreduced buffy coat derived platelet concentrates photochemically treated with amotosalen HCI and ultraviolet A light stored up to 7 days: assessment of hemostatic function under flow conditions. Transfusion 2007; 47(4): 666-671.
   View abstract >
10. Castro E, Gironés N, Bueno JL, et al. The efficacy of photochemical treatment with amotosalen HCl and UVA (INTERCEPTTM) for inactivation of Trypanosoma cruzi in pooled buffy-coat platelets. Transfusion 2007, 47(3):434-441.
    View abstract >
11. Isola H, Kientz D, Aleil B, et al. In vitro evaluation of Haemonetics MCS+ apheresis platelet concentrates treated with photochemical pathogen inactivation following plasma volume reduction using the INTERCEPT Preparation Set. Vox Sang 2006;90(2):128-30.
12. Murphy S, Snyder E, Cable R, et al. Platelet dose consistency and its effect on the number of platelet transfusions for support of thrombocytopenia: an analysis of the SPRINT trial of platelets photochemically treated with amotosalen HCl and ultraviolet A light. Transfusion 2006;46(1):24-33.
13. Pineda A, McCullough J, Benjamin RJ, et al. Pathogen inactivation of platelets with a photochemical treatment with amotosalen HCl and ultraviolet light: process used in the SPRINT trial. Transfusion 2006;46(4):562-71.
14. Roback JD, Conlan M, Drew WL, et al. The role of photochemical treatment with amotosalen and UVA light in the prevention of transfusion-transmitted cytomegalovirus infections. Transfus Med Rev 2006;20(1):45-56.
15. Simonsen AC, Johansson PI, Conlan MG, et al. Transfusion of 7-day-old amotosalen photochemically treated buffy-coat platelets to patients with thrombocytopenia: a pilot study. Transfusion 2006;46(3):424-33.
16. Slichter SJ, Raife TJ, Davis K, et al. Platelets photochemically treated with amotosalen HCl and ultraviolet A light correct prolonged bleeding times in patients with thrombocytopenia. Transfusion 2006;46(5):731-40.
17. Snyder E, McCullough J, Slichter SJ, et al. Clinical safety of platelets photochemically treated with amotosalen HCl and ultraviolet A light for pathogen inactivation: the SPRINT trial. Transfusion 2005;45(12):1864-75.
18. Schlenke P, Kirchner H, Corash L. Concerning Caspari et al: Pathogen Inactivation of Cellular Blood Products-- More Security for the Patient or Less? Transfusion Medicine and Hemotherapy 2005;32(1):45-8.
19. Postma MJ, van Hulst M, De Wolf JT, et al. Cost-effectiveness of pathogen inactivation for platelet transfusions in the Netherlands. Transfus Med 2005;15(5):379-87.
20. Pinna D, Sampson-Johannes A, Clementi M, et al. Amotosalen photochemical inactivation of severe acute respiratory syndrome coronavirus in human platelet concentrates. Transfus Med 2005;15(4):269-76.
21. Lin L, Hanson CV, Alter HJ, et al. Inactivation of viruses in platelet concentrates by photochemical treatment with amotosalen and long-wavelength ultraviolet light. Transfusion 2005;45(4):580-90.
22. Lin L, Conlan MG, Tessman J, et al. Amotosalen interactions with platelet and plasma components: absence of neoantigen formation after photochemical treatment. Transfusion 2005;45(10):1610-20.
23. Jauvin V, Alfonso RD, Guillemain B, et al. In vitro photochemical inactivation of cell-associated human T-cell leukemia virus Type I and II in human platelet concentrates and plasma by use of amotosalen. Transfusion 2005;45(7):1151-9.
24. Janetzko K, Cazenave JP, Kluter H, et al. Therapeutic efficacy and safety of photochemically treated apheresis platelets processed with an optimized integrated set. Transfusion 2005;45(9):1443-52.
25. Eastman RT, Barrett LK, Dupuis K, et al. Leishmania inactivation in human pheresis platelets by a psoralen (amotosalen HCl) and long-wavelength ultraviolet irradiation. Transfusion 2005;45(9):1459-63.
26. Bruchmuller I, Losel R, Bugert P, et al. Effect of the psoralen-based photochemical pathogen inactivation on mitochondrial DNA in platelets. Platelets 2005;16(8):441-5.
27. Bruchmuller I, Janetzko K, Bugert P, et al. Polymerase chain reaction inhibition assay documenting the amotosalen-based photochemical pathogen inactivation process of platelet concentrates. Transfusion 2005;45(9):1464-72.
28. Blajchman MA, Beckers EA, Dickmeiss E, et al. Bacterial Detection of Platelets: Current Problems and Possible Resolutions. Transfus Med Rev 2005;19(4):259-72.
29. Benjamin RJ. Bacterial detection in platelet components and the rationale for pathogen inactivation: A blood center perspective. J Clin Apheresis 2005;20(2):117-22.
30. Allain JP, Bianco C, Blajchman MA, et al. Protecting the blood supply from emerging pathogens: the role of pathogen inactivation. Transfus Med Rev 2005;19(2):110-26.
31. Wollowitz S. Targeting DNA and RNA in Pathogens: Mode of Action of Amotosalen HCl. Transfusion Medicine and Hemotherapy 2004;31(Suppl. 1):11-6.
32. van Rhenen DJ, Gulliksson H, Cazenave JP, et al. Therapeutic efficacy of pooled buffy-coat platelet components prepared and stored with a platelet additive solution. Transfus Med 2004;14(4):289-95.
33. Staginnus U, Corash L. Economics of pathogen inactivation technology for platelet concentrates in Japan. Int J Hematol 2004;80(4):317-24.
34. Snyder E, Raife T, Lin L, et al. Recovery and life span of ¹¹¹indium-radiolabeled platelets treated with pathogen inactivation with amotosalen HCl (S-59) and ultraviolet A light. Transfusion 2004;44(12):1732-40.
35. Schlenke P. Protection against Transfusion-Associated Graft-versus-Host Disease in Blood Transfusion: Is Gamma-Irradiation the Only Answer? Transfusion Medicine and Hemotherapy 2004;31(Suppl. 1):24-31.
36. Picker SM, Speer R, Gathof BS. Functional characteristics of buffy-coat PLTs photochemically treated with amotosalen-HCl for pathogen inactivation. Transfusion 2004;44(3):320-9.
37. Picker SM, Speer R, Gathof BS. Evaluation of processing characteristics of photochemically treated pooled platelets: target requirements for the INTERCEPT Blood System comply with routine use after process optimization. Transfus Med 2004;14(3):217-23.
38. Moog R, Frohlich A, Mayaudon V, Lin L. In vitro evaluation of COM.TEC apheresis platelet concentrates using a preparation set and pathogen inactivation over a storage period of five days. J Clin Apheresis 2004;19(4):185-91.
39. McCullough J, Vesole DH, Benjamin RJ, et al. Therapeutic efficacy and safety of platelets treated with a photochemical process for pathogen inactivation: the SPRINT Trial. Blood 2004;104(5):1534-41.
40. Ljungman P. Risk of cytomegalovirus transmission by blood products to immunocompromised patients and means for reduction. Br J Haematol 2004;125(2):107-16.
41. Lin L, Dikeman R, Molini B, et al. Photochemical treatment of platelet concentrates with amotosalen and long-wavelength ultraviolet light inactivates a broad spectrum of pathogenic bacteria. Transfusion 2004;44(10):1496-504.
42. Jordan CT, Saakadze N, Newman JL, et al. Photochemical treatment of platelet concentrates with amotosalen hydrochloride and ultraviolet A light inactivates free and latent cytomegalovirus in a murine transfusion model. Transfusion 2004;44(8):1159-65.
43. Janetzko K, Lin L, Eichler H, et al. Implementation of the INTERCEPT Blood System for Platelets into routine blood bank manufacturing procedures: evaluation of apheresis platelets. Vox Sang 2004;86(4):239-45.
44. Corash L, Lin L. Novel processes for inactivation of leukocytes to prevent transfusion-associated graft-versus-host disease. Bone Marrow Transplant 2004;33(1):1-7.
45. Van Voorhis WC, Barrett LK, Eastman RT, et al. Trypanosoma cruzi inactivation in human platelet concentrates and plasma by a psoralen (amotosalen HCl) and long-wavelength UV. Antimicrob Agents Chemother 2003;47(2):475-9.
46. van Rhenen D, Gulliksson H, Cazenave J-P, et al. Transfusion of pooled buffy coat platelet components prepared with photochemical pathogen inactivation treatment: the euroSPRITE trial. Blood 2003;101(6):2426-33.
47. Corash L. Pathogen reduction technology: methods, status of clinical trials, and future prospects. Curr Hematol Rep 2003;2(6):495-502.
48. Bell CE, Botteman MF, Gao X, et al. Cost-effectiveness of transfusion of platelet components prepared with pathogen inactivation treatment in the United States. Clin Ther. 2003;25(9):2464-86.
49. Janetzko K, Klinger M, Mayaudon V, et al. Storage Characteristics of Split Double-Dose Platelet Concentrates Derived from Apheresis and Treated with Amotosalen Hydrochloride and UVA Light for Pathogen Inactivation. Transfusion Medicine and Hemotherapy 2002;29(4):193-8.
50. Janetzko K, Corash L, Lin L, et al. In vitro function of double-dose platelets treated with the pathogen inactivation Helinx™ technology. In: Holick MF, ed. Biologic Effects of Light 2001. Boston, MA: Kluwer Academic Publishers, 2002:313-23.
51. Wollowitz S. Fundamentals of the psoralen-based Helinx technology for inactivation of infectious pathogens and leukocytes in platelets and plasma. Semin Hematol 2001;38(4 Suppl 11):4-11.
52. Lin L. Inactivation of cytomegalovirus in platelet concentrates using Helinx technology. Semin Hematol.. 2001; 38(4 Suppl 11):27-33.
53. Ciaravino V, McCullough T, Dayan AD. Pharmacokinetic and toxicology assessment of INTERCEPT (S-59 and UVA treated) platelets. Hum Exp Toxicol. 2001;20(10):533-50.
54. Ciaravino V. Preclinical safety of a nucleic acid-targeted Helinx compound: a clinical perspective. Semin Hematol. 2001;38(4 Suppl 11):12-9.
55. van Rhenen DJ, Vermeij J, Mayaudon V, et al. Functional characteristics of S-59 photochemically treated platelet concentrates derived from buffy coats. Vox Sang 2000;79(4):206-14.
56. Knutson F, Alfonso R, Dupuis K, et al. Photochemical inactivation of bacteria and HIV in buffy-coat-derived platelet concentrates under conditions that preserve in vitro platelet function. Vox Sang. 2000;78(4):209-16.
57. Hei DJ, Grass J, Lin L, et al. Elimination of cytokine production in stored platelet concentrate aliquots by photochemical treatment with psoralen plus ultraviolet A light. Transfusion 1999;39(3):239-48.
58. Grass JA, Wafa T, Reames A, et al. Prevention of transfusion-associated graft-versus-host disease by photochemical treatment. Blood 1999;93(9):3140-7.
59. Lin L, Alfonso R, Behrman B, et al. Photochemical treatment of platelet concentrates with a novel psoralen and UVA to enhance the safety of platelet transfusions. Transfusion Medicine and Hemotherapy 1998;25(1):39-48.
60. Lin L. Psoralen photochemical treatment of platelets. Science and Medicine 1998;5(1):54-63.
61. Grass JA, Hei DJ, Metchette K, et al. Inactivation of leukocytes in platelet concentrates by photochemical treatment with psoralen plus UVA. Blood 1998;91(6):2180-8.
62. Lin L, Cook DN, Wiesehahn, GP, et al. Photochemical inactivation of viruses and bacteria in platelet concentrates by use of a novel psoralen and long-wavelength ultraviolet light. Transfusion 1997;37(4):423-35.